Performance. Defined.

InVitria Blog | Cell Culture and Biotech Manufacturing Insights

Jeanne McAdara Ph.D.

Jeanne McAdara Ph.D.
Dr. McAdara is part of InVitria's medical and scientific communications team. She has been involved in scientific communications for 19 years and is the Principal of Biolexica Health Science Communications. Dr. McAdara earned her Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute and was a postdoctoral fellow in the Jonsson Comprehensive Cancer Center, where she studied the biochemical and cellular mechanisms underlying leukemia.
Find me on:

Recent Posts

Cellastim S Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells

Posted By Jeanne McAdara Ph.D. on 5/9/19 11:00 AM

The number and breadth of applications for induced human embryonic and pluripotent stem cells (hi-ESCs and hi-PSCs) in both research and clinical settings continue to co-evolve with our understanding of how to harness them as biological tools.

Read More

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Posted By Jeanne McAdara Ph.D. on 4/16/19 2:00 PM

Enhanced liquid-phase stability of live-attenuated Flavivirus vaccines using recombinant albumin

The single-stranded RNA viruses belonging to the genus Flavivirus (family, Flaviviridae) are significant to global public health due to the high rates of morbidity and mortality they cause.1 For example, Yellow Fever sickens approximately 200,000 people and kills 30,000 annually.2 Other viruses belonging to this genus include the mosquito-borne diseases Dengue Fever, Japanese encephalitis, West Nile virus, and Zika virus, and the tick-borne diseases Tick-borne Encephalitis, Kyasanur Forest Disease, Alkhurma disease, and Omsk hemorrhagic fever.

Read More

Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial

Posted By Jeanne McAdara Ph.D. on 2/19/19 10:00 AM

On Tuesday, the vaccine company FluGen announced promising preliminary results from a placebo-controlled, Phase 2 clinical trial of their investigational intranasal influenza vaccine, M2SR, in 99 healthy adults challenged with the A/Belgium/4217/2015, H3N2 strain.

Read More